VPI, Ashish to collaborate on vet pharma formulations

Published on: Jul 29, 2013

Vets Plus Inc. (VPI) and Ashish Life Science Pvt. Ltd. announced July 29 that the two animal nutrition and health companies will be partnering to develop pharmaceutical formulations for veterinary health.

VPI is a U.S.-based manufacturer of nutritional supplements for all species, specializing in nutraceuticals. Ashish Life Science, based in India, focuses on veterinary drugs.

The collaboration is expected to result in multiple pharmaceuticals utilizing the strengths of each company's existing research teams, an announcement said.

VPI president and chief executive officer Raj Lall said, "The series of veterinary products we develop with Ashish Life Science will complement our current capabilities."

While Vets Plus has always focused on non-drug approaches to health, Lall said, "Our research and development team has a great range of scientific expertise; Ashish Life Science has expertise and production capability in the pharmaceutical field. Pooling our scientific resources and sharing our research will allow us to better serve the industry with innovative solutions for animal health."

Lall emphasized that while the production of jointly developed pharmaceuticals would take place in Ashish's India facility, manufacturing of supplements would continue at VPI's Menomonie, Wis., headquarters.

He said, "We are not closing down any of our current manufacturing lines. This partnership will only expand our capabilities."

The partnership also includes an exclusive agreement for distribution in the U.S. VPI will be the sole distributor of all Ashish Life Science nutritional and feed supplement products, as well as the drug products resulting from the collaborative research.